Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using ...
Genetic Diagnostic Technology A Game Changer For Rare Diseases, But Ethics Concerns Linger
Genetic diagnostic technology advances for rare diseases offer hope, but gene-tech comes wrapped in complex ethical concerns. Currently, rare disease patients take an average of five years to get a diagnosis, with many misdiagnoses. So will Europe accelerate modern diagnostics, or will ethical concerns stifle innovation?
Around 30 million Europeans are living with a rare disease, and less than 5% of rare conditions are effectively treated. For rare diseases that do not present symptoms early on, newborn screening programs are important, especially when early intervention may prevent symptoms or disease progression, as EURORDIS-Rare Disease Europe points out.
"The best way to reduce the whole diagnosis odyssey remains access to new-born screening because it can shorten the time it takes to see a doctor, but also to have access to a diagnosis once you have had the first consultation" said Jessie Dubief, Social Research Director for EURORDIS, during the European Conference on Rare Diseases and Orphan Products (ECRD) on 15 May, in Brussels.
More than 70% of rare diseases have genetic origins. As scientific knowledge advances and genome sequencing technology improves, the question that has become even more significant is whether newborn screening programs should expand and include new sequencing techniques.
"It could change children's lives. You can diagnose a rare disease at a time that allows you to treat them effectively because you 'caught it' early on," Theoklis Zaoutis, Professor of paediatrics and former president of EODY, the Greek public health agency, told Euractiv.
New-born screening acceptance
A recent comprehensive survey by EURORDIS showed broad support from the rare disease community for newborn screening as an essential early healthcare intervention.
Of the participants, 73% either strongly agreed or agreed, that they would have liked to have been diagnosed at birth or for a family member living with a rare disease to have been diagnosed at birth.
Also, when looking at surveys at the general population level this idea was even more widely accepted, remarked Dubief while presenting the study's results at ECRD.
Additionally, 90% of respondents think that any rare disease should be screened at birth if it would lead to a quicker diagnosis, a diagnosis that would benefit both the patient and their family, if it would allow better recognition of a person's disabilities, and promote rare disease follow-up and harm avoidance, through prevention.
"It is crucial that European policymakers, at both the national and international levels, act now to diminish disparities in new-born screening programmes across different countries, enhancing the quality of life for all children, irrespective of their birthplace," said Virginie Bros-Facer, the new CEO of EURORDIS.
"It is high time that advancements in public policy catch up with the scientific and technological advancements that we have seen in diagnostics," she added.
As Jann Le Cam, Founder and Past Chief Executive Officer of EURORDIS, commented to Euractiv, what should be done is to "agree at the European level on what level of evidence we need to show the benefit of having a new-born screening program and to have also studied on the health economy of that."
Then, he said, "Based on this evidence, which can be collected a few years before the approval of medicines, make a decision and link access to the medicines with newborn screening."
Genome sequencing possibilities
In the last decades, genomic sequencing technologies have gradually become important in understanding disease, improving, and shortening the diagnostic path, and identifying targets or mechanisms that medicines could affect.
As more targeted medicines are developed, it is also crucial to identify the patient who would benefit the most at the right time.
To further understand the ability of sequencing babies' genomes to discover rare genetic conditions earlier, Genomics England is running an NHS-embedded research study.
"It aims to look at the DNA of over 100,000 babies and gather evidence to consider whether whole genome sequencing could be rolled out as part of a future newborn screening programme," as it is described. The initial list holds over 200 rare conditions that will be looked for.
On the other side of Europe, another study involving 'New-born Sequencing' is being rolled out in Greece.
First Steps Initiative
The First Steps initiative is a national program that uses whole genome sequencing (WGS) as a screening tool for newborns to identify genetic conditions before symptoms present.
As Petros Tsipouras, CEO of PlumCare and scientific director of First Steps, explained during ECRD, the first part of the study plans to enrol at least 1,000 families through three university hospitals in Greece by the end of this year.
"We have a mandate from the Greek government to screen 100,000 babies in the next three years," he explained, adding that phase II will aim to include 20,000 babies starting in 2025, while phase III will aim to screen all babies born in Greece.
It screens for 510 diseases for which there is an intervention. It is an informed consent-based clinical study. It is under the auspices of EODY.
"WGS technology provides a tremendous opportunity for us to expand our newborn screening programs. As you know, there are many rare diseases that we do not necessarily screen for presently, and it won't be cost-effective at this time to screen for them," Professor Zaoutis told Euractiv.
"Whole genome screening provides the kind of technology that allows us to identify rare diseases and act on them because there are some rare conditions that, if you catch them early on, you could change the outcome of the child's life," he underlined.
As he explained, WGS's basic advantage is that you can screen for hundreds of rare diseases with one sample.
"Rapid WGS within 18 to 24 hours can be lifesaving. 37% of babies admitted to an ICU have an underlying genetic problem, for which having rapid WGS and introducing an intervention is lifesaving," Tsipouras highlighted.
Ethical aspects
The advancement and wider use of genetic testing isn't the only focus of discussion, though. With the progression of screening technology, ethical concerns have risen.
As has been reported, ethical aspects concern, among others, the procedure of genetic testing for rare diseases (such as obtaining informed consent or interpreting the test results), the delivery of results, the decisions that follow, and the possibility of facing stigma and discrimination from the outcome.
This point was also made during the discussion in ECRD.
"If we want to bring real equity across a country's population, new-born sequencing can do that, as you screen all babies born in the country, so there is no discrimination," Tsipouras commented.
However, he added: "Feasibility, clinical utility and societal acceptance need to be in place before a public health measure is established."
"A public debate is needed on [the issue of new-born sequencing] because it is the future. We must drive [the discussion] on this pathway we are moving on. It should be an informed decision; we have to raise awareness on all the challenges and advantages," Simona Bellagambi, from the Italian rare disease federation UNIAMO, said during the discussion in ECRD.
"Data confidentiality; a person's genome should be accessed only by them and not be publicly available. If it is, identifiers should be omitted, and data should be anonymised," Zaoutis said.
"We must put in place all the necessary safeguards around data and privacy protection," he concluded.
"We need to go stepwise, but that's certainly not a reason not to scale up," Le Cam had commented on the issue, adding that "it's not a good route neither to immediately move to large-scale genome sequencing without further study and evaluation of that new knowledge."
"We need time to generate more knowledge because we see some of the benefits, but we also see some of the risks," he concluded.
[By Vasiliki Angouridi, Edited by Brian MaguireEuractiv's Advocacy Lab]
Read more with EuractivDemystifying The Maze: How Genetic Testing Lights The Path In India's Fight Against Rare Diseases
For countless families in India, rare diseases are a crippling burden. Affecting less than 1 in 50,000 individuals, these conditions often leave patients and doctors entangled in a frustrating diagnostic labyrinth. Traditional methods can lead to delays and misdiagnosis, further jeopardizing timely intervention. However, a beacon of hope emerges in the form of genetic testing, a tool with the potential to transform the fight against rare diseases, especially considering the exorbitant costs of treatments. Unlocking the door to early intervention: The crucial role of genetic testingGenetic testing provides a precise approach, analyzing an individual's DNA to pinpoint the underlying genetic mutations responsible for the disease. This accuracy is particularly crucial in India's diverse population. Early and accurate diagnosis is the cornerstone for effective treatment, and in the face of rare diseases with astronomically high treatment costs, every day counts. Imagine the stark difference between a prompt diagnosis leading to potential gene therapy intervention and a delayed diagnosis followed by years of managing symptoms. Genetic testing empowers physicians to intervene early, potentially preventing disease progression and the associated financial strain.The high stakes of rare diseases: A look at costly treatmentsConsider Spinal Muscular Atrophy (SMA), a debilitating neuromuscular disorder in infants. The life-saving gene therapy injection, Zolgensma, carries a price tag of a staggering ₹16 crore. Similarly, Gaucher's disease, a lysosomal storage disorder, requires enzyme replacement therapy costing lakhs of rupees annually. These costs can cripple families, pushing them into a cycle of debt and despair.Prevention as a powerful weapon: The value of carrier screening Genetic testing goes beyond diagnosis. It can reveal carrier status, informing individuals if they carry a gene mutation for a rare disease without exhibiting symptoms themselves. This knowledge empowers couples to make informed decisions about family planning. Carrier screening programs can identify couples at increased risk of having children with a specific rare disease. This allows them to consider prenatal testing or preimplantation genetic diagnosis (PGD). Early detection during pregnancy allows for informed decision-making, potentially preventing the financial and emotional burden associated with these rare diseases.The promise of gene therapy: A glimmer of hopeGene therapy offers a transformative approach for treating rare diseases caused by single-gene mutations. By introducing a healthy copy of the gene or correcting the faulty one, gene therapy has the potential to provide a cure or significantly improve a patient's condition. While still in its early stages, gene therapy holds immense promise, especially when weighed against the astronomical costs of current treatment options.Building a brighter future: A collective effort to make healthcare affordableIndia is on the right track in its fight against rare diseases. By increasing investment in infrastructure, expanding genetic testing facilities, and training more genetic specialists, the nation can empower its healthcare system for efficient diagnosis and potentially reduce reliance on expensive treatments later. Raising public awareness about rare diseases and the role of genetic testing is equally important.Meet a medical geneticist: Navigating the maze of genetic testsGiven the vast array of over 100 genetic tests available, consulting a medical geneticist is crucial. A medical geneticist is a physician with specialized training in diagnosing and managing genetic disorders. They will consider your family history, symptoms, and potential risk factors to determine the most appropriate genetic test(s) for your situation. Here's what to expect during your consultation:● Detailed discussion of your medical history and family history.● A physical examination, if necessary.● Review of your symptoms and concerns.● Explanation of the different types of genetic tests available and their suitability for your situation.● Discussion of the benefits, risks, and limitations of genetic testing.● Guidance on interpreting the test results and their implications for your health.Genetic testing - A beacon of hope in a sea of high costsIn the face of rare diseases with exorbitant treatment costs, genetic testing emerges as a powerful tool. By enabling early diagnosis, potentially paving the way for preventive measures, and informing treatment decisions, genetic testing empowers patients and families to navigate this challenging terrain. With a collective effort focused on affordability and accessibility, genetic testing can become a game-changer, offering hope and a brighter future for those battling rare diseases in India.(Author: Dr Richa Soni, Consultant, Medical geneticist, Fortis Gurugram)Global Adiponectin Testing Market Set For Robust Growth With A 7.9% CAGR From 2022 To 2032
Adiponectin Testing MarketThe global adiponectin testing market is on the brink of significant expansion, with an impressive projected Compound Annual Growth Rate (CAGR) of 7.9% over the forecast period from 2022 to 2032. Recent market analyses reveal that the market, valued at USD 45.11 billion in 2022, is expected to exceed USD 89 billion by 2032.
The surge in sales of adiponectin testing kits can be attributed to their critical role in the pathogenesis of dyslipidemia. Adiponectin, a crucial biomarker, significantly affects HDL and LDL metabolism, making these testing kits essential in healthcare settings across the globe.
Adiponectin's importance extends beyond lipid metabolism. It plays a vital role in regulating energy substrate metabolism and body composition, thereby exerting a substantial influence on various bodily functions. This pivotal role in maintaining health is driving the steady increase in demand for adiponectin testing kits.
Get Access to Sample Now: https://www.Futuremarketinsights.Com/reports/sample/rep-gb-10629
Moreover, the utilization of adiponectin ELISA kits and enzyme immunoassay kits for both diagnostic and research purposes is further driving the market growth. The surge in healthcare awareness, particularly in developing regions, is expected to fuel the demand for adiponectin testing kits in the foreseeable future.
Furthermore, adiponectin's pivotal role in modulating lipid and glucose metabolism has led to increased sales of testing kits. Reduced adiponectin levels, commonly observed in genetic and diet-induced murine models of obesity, underscore the importance of monitoring adiponectin levels for mediating insulin action or resistance.
As the global healthcare landscape evolves, the importance of adiponectin testing in diagnosing and managing metabolic disorders becomes increasingly evident. With the market projected to expand significantly in the coming years, stakeholders are poised to capitalize on emerging opportunities in this dynamic sector.
Various Factors Impact The Adiponectin Testing Market, Both Positively And Negatively:
Overall, the adiponectin testing market is influenced by a combination of factors related to economic conditions, healthcare infrastructure, technological advancements, and awareness levels among healthcare professionals and the general population.Top of Form
Request Customization Available: https://www.Futuremarketinsights.Com/customization-available/rep-gb-10629
Key companies profiled:
Global Adiponectin Testing Market Segmentation:
By Product Type:
By Species Type:
By End User:
By Region:
Get Full Report Now: https://www.Futuremarketinsights.Com/checkout/10629
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
Comments
Post a Comment